Aarkstore - Glycine Transporter Type-1 (Glyt-1) Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Glycine Transporter Type-1 (Glyt-1) Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0eab-NmI3M



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Glycine Transporter Type-1 (Glyt-1) Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Glycine Transporter Type-1 (Glyt-1) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Glycine Transporter Type-1 (Glyt-1) Inhibitors – PowerPoint PPT presentation

Number of Views:5

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Glycine Transporter Type-1 (Glyt-1) Inhibitors -Pipeline Insights, 2014


1
Glycine Transporter Type-1 (Glyt-1) Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/73731/glycine-transporter-type-1-glyt-1-inhibito
    rs-pipeline-insights-2014

2
Summary
  • DelveInsights,Glycine Transporter Type-1 (Glyt-1)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Glycine Transporter Type-1 (Glyt-1)
    Inhibitors. This report provides information on
    the therapeutic development based on the Glycine
    Transporter Type-1 (Glyt-1) Inhibitors dealing
    with mechanism of action, comparative analysis at
    various stages covering Filed, Phase III, Phase
    II, Phase I, IND filed, Preclinical, Discovery
    and unknown stages, therapeutics assessment by
    monotherapy and combination products and molecule
    type drug information. The report also covers the
    companies information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts. Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases. Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Glycine Transporter
    Type-1 (Glyt-1) Inhibitors The report provides
    pipeline products under drug profile section
    which includes product description, MOA,
    licensors collaborators, development partner
    and chemical information Coverage of the Glycine
    Transporter Type-1 (Glyt-1) Inhibitors pipeline
    on the basis of target, MOA, route of
    administration, technology involved and molecule
    type The report reviews key players involved in
    the therapeutics development for Glycine
    Transporter Type-1 (Glyt-1) Inhibitors and also
    provide company profiling The report also gives
    the information of dormant and discontinued
    pipeline projects  Pipeline products coverage
    based on various stages of development ranging
    from preregistration till discovery and
    undisclosed stages  Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete MOA intelligence and
    complete understanding over therapeutics
    development for Glycine Transporter Type-1
    (Glyt-1) Inhibitors Identify the relationship
    between the drugs and use it for target finding,
    drug repurposing, and precision medicine. Devise
    corrective measures for pipeline projects by
    understanding Glycine Transporter Type-1 (Glyt-1)
    Inhibitors pipeline depth and focus of Indication
    therapeutics  Developing strategic initiatives to
    support your drug development activities. Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope Provides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies  Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipeline Gaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

7
Table of Content
  • Glycine Transporter Type-1 (Glyt-1) Inhibitors
    Overview Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Disease Associated Glycine Transporter
    Type-1 (Glyt-1) Inhibitors Pipeline
    Therapeutics Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Therapeutics under Development by
    Companies  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Late Stage Products (Filed and Phase
    III) Comparative Analysis  Glycine Transporter
    Type-1 (Glyt-1) Inhibitors Mid Clinical Stage
    Products (Phase II) Comparative Analysis  Glycine
    Transporter Type-1 (Glyt-1) Inhibitors Early
    Clinical Stage Products (Phase I and IND
    Filed) Comparative Analysis  Glycine Transporter
    Type-1 (Glyt-1) Inhibitors Discovery and
    Pre-Clinical Stage Products  Comparative
    Analysis  Drug Candidate Profiles

8
Table of Content
  • Glycine Transporter Type-1 (Glyt-1) Inhibitors
    Therapeutics Assessment  Assessment by
    Monotherapy Products  Assessment by Combination
    Products  Assessment by Route of
    Administration  Assessment by Molecule
    Type  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Discontinued Products  Glycine
    Transporter Type-1 (Glyt-1) Inhibitors Dormant
    Products Companies Involved in Therapeutics
    Development for Glycine Transporter Type-1
    (Glyt-1) Inhibitors  Appendix  Methodology  Contac
    t Us  Disclaimer

9
List of Tables
  • Number of Products under Development for Glycine
    Transporter Type-1 (Glyt-1) Inhibitors by Therapy
    Area, 2014 Number of Products under Development
    for Glycine Transporter Type-1 (Glyt-1)
    Inhibitors, 2014 Number of Products under
    Development by Companies  Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014 Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014 Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014 Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014 Drug Candidates Profiles

10
List of Tables
  • Glycine Transporter Type-1 (Glyt-1) Inhibitors
    Assessment by Monotherapy Products  Glycine
    Transporter Type-1 (Glyt-1) Inhibitors Assessment
    by Combination Products  Glycine Transporter
    Type-1 (Glyt-1) Inhibitors Assessment by Route of
    Administration  Glycine Transporter Type-1
    (Glyt-1) Inhibitors Assessment by Stage and Route
    of Administration  Glycine Transporter Type-1
    (Glyt-1) Inhibitors Assessment by Molecule
    Type  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Assessment by Stage and Molecule
    Type  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Therapeutics Discontinued
    Products  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Therapeutics Dormant Products Products
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Glycine
    Transporter Type-1 (Glyt-1) Inhibitors by Therapy
    Area, 2014 Number of Products under Development
    for Glycine Transporter Type-1 (Glyt-1)
    Inhibitors, 2014 Late Clinical Stage Products
    (Filed and Phase III), 2014 Mid Clinical Stage
    Products (Phase II), 2014 Early Clinical Stage
    Products (Phase I and IND Filed), 2014 Discovery
    and Pre-Clinical Stage Products, 2014 Glycine
    Transporter Type-1 (Glyt-1) Inhibitors Assessment
    by Monotherapy Products  Glycine Transporter
    Type-1 (Glyt-1) Inhibitors Assessment by
    Combination Products  Glycine Transporter Type-1
    (Glyt-1) Inhibitors Assessment by Route of
    Administration  Glycine Transporter Type-1
    (Glyt-1) Inhibitors Assessment by Stage and Route
    of Administration  Glycine Transporter Type-1
    (Glyt-1) Inhibitors Assessment by Molecule
    Type  Glycine Transporter Type-1 (Glyt-1)
    Inhibitors Assessment by Stage and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Glycine Transporter Type-1 (Glyt-1) Inhibitors
    -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Glycine Transporter Type-1 (Glyt-1)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com